Drug news and alerts
Get the latest news on drug recalls, safety alerts, new therapies and other important updates.
Drug recall notice for NP Thyroid® Tablets
April 30, 2021
The U.S. Food and Drug Administration (FDA) announced that Acella Pharmaceuticals, LLC is voluntarily recalling thirty-eight (38) lots of NP Thyroid®, Thyroid Tablets, USP. The products are being recalled because testing has found these lots to be sub potent, meaning they don’t provide the amount of relief per dose as expected. If you take NP Thyroid tablets, speak with your health care professional as soon as possible to see if there are other available medicines for you.
Drug recall notice for Guanfacine
April 20, 2021
Apotex Corp is voluntarily recalling one (3) lots of Guanfacine ER Tablets, 2 mg to the consumer level due to trace amounts of Quetiapine Fumarate.
Drug recall notice for Telmisartan tablets
April 6, 2021
Alembic Pharmaceuticals Inc is voluntarily recalling one (1) lot of Telmisartan Tablets, 20 mg to the consumer level due to a label mix-up.
Drug recall notice for New Anagrelide
December 17, 2020
Torrent Pharmaceuticals Limited is voluntarily recalling one (1) lot of Anagrelide Capsules, USP to the consumer level due to dissolution test failure detected during routine quality testing.
Drug recall notice Metformin extended-release products
October 9, 2020
Sun Pharma is voluntarily recalling one lot of RIOMET ER™ (metformin hydrochloride extended-release oral suspension), 500 mg per 5 mL to the consumer level. The reason for the recall is due to the level of N-Nitrosodimethylamine (NDMA), which has been found to be above the allowable Acceptable Daily Intake (ADI) limit established by the U.S. Food and Drug Administration.
Drug recall notice for nizatidine
May 4, 2020
The Food and Drug Administration (FDA) has issued a recall for nizatidine oral solution, a drug used for the short-term treatment (up to 8 weeks) of active duodenal ulcers and active benign gastric ulcers, as maintenance therapy for duodenal ulcer patients for up to one year, and for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis and associated heartburn due to gastroesophageal reflux disease (GERD).
Drug recall notice for tetracycline
April 30, 2020
The Food and Drug Administration (FDA) has issued a recall for tetracycline, a drug used to treat infections including upper and lower respiratory infections and skin and soft tissues infections.
Drug recall notice for ranitidine
April 13, 2020
The Food and Drug Administration (FDA) has issued a recall for all ranitidine products, a drug used to treat ulcers and other conditions where reduction of gastric secretion and acid output is desirable.
Drug recall notice for phenytoin oral suspension
March 4, 2020
The manufacturer of phenytoin is voluntarily recalling this medicine because it may not re-suspend when shaken, which could result in under or over-dosing
Drug recall notice for lorcaserin
February 21, 2020
The Food and Drug Administration (FDA) has issued a voluntary recall of lorcaserin drugs due to an impurity used in the manufacturing of these medicines.
Drug recall notice for nizatidine
January 29, 2020
The Food and Drug Administration (FDA) has issued a voluntary recall of nizatidine drugs due to an impurity used in the manufacturing of these medicines.
Ongoing drug recall notice for ranitidine
January 16, 2020
The FDA continues to monitor and may add more manufacturers to the recall for ranitidine, a drug used to treat ulcers and other conditions where reduction of gastric secretion and acid output is desirable.
Drug recall notice for Natpara
September 26, 2019
The manufacturer of NATPARA, a drug used to treat hypocalcemia in patients with hypoparathyroidism, is issuing a recall of all doses on the market because of a potential issue.
Drug recall notice for irbesartan and irbesartan-containing drug products
January 21, 2019
The Food and Drug Administration (FDA) has issued a voluntary recall of select irbesartan-containing drugs due to an impurity used in the manufacturing of these medicines.
Drug recall notice for losartan and losartan-containing drug products
January 4, 2019
The Food and Drug Administration (FDA) has issued a voluntarily recall of select losartan containing drugs due to an impurity used in the manufacturing of these medicines.
Drug recall notice for valsartan and valsartan containing drug products
November 20, 2018
The Food and Drug Administration (FDA) has issued a voluntary recall of select generic valsartan and valsartan containing drugs due to an impurity used in the manufacturing of these medicines.
Drug recall notice for ondansetron orally disintegrating tablets and risperidone orally disintegrating tablets
August 6, 2018
Novartis and Sandoz Inc. have voluntarily recalled certain blister card packages distributed in the U.S.
Drug recall notice for Ventolin HFA Inhaler
June 1, 2017
The maker of Ventolin HFA Inhaler® has voluntarily recalled select lots from the U.S. marketplace. This recall was initiated due to a defect in certain lots of the inhaler that causes the product to deliver fewer doses than indicated.
Drug recall notice for EpiPen and EpiPen Jr Auto-Injector
June 1, 2017
The maker of EpiPen® and EpiPen Jr® Auto-Injectors has voluntarily recalled selected lots distributed in the U.S. and other markets. This recall was initiated due to reports of possible device malfunctions that could result in the devices failing to activate or requiring increased force to activate in an emergency or life-threatening situation.